Hint mode is switched on Switch off
For swift navigation between sections

Poseida Therapeutics
LEI 549300USKSDMNGMN8V04

PDF download

Choose all Reset all
Download Cancel
Organization name
Poseida Therapeutics Inc
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging its proprietary next-generation, non-viral gene engineering technologies to create life-saving cell therapeutics for patients with high unmet medical need.

Awards

News

07/11/2024 Poseida Therapeutics: Results Of Operations And Financial Condition, Financial Statements And Exhibits
27/09/2024 Poseida Therapeutics: Other Events
30/04/2024 Poseida Therapeutics: Of This Report (including Exhibit 99.1) Is Furnished And Shall Not Be Deemed Filed For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended, Or Subject To The Liabilities Of That Section Or Sections 11 And 12(a)(2) Of The Securities Act Of 1933, As Amended. The Information Shall Not Be Deemed Incorporated By Reference Into Any Other Filing With The Securities And Exchange Commission Made By The Company, Whether Made Before Or After Today S Date, Regardless Of Any General Incorporation Language In Such Filing, Except As Shall Be Expressly Set Forth By Specific References In Such Filing, Financial Statements And Exhibits
17/04/2024 Poseida Therapeutics: Of This Report (including Exhibits 99.1 And 99.2) Is Furnished And Shall Not Be Deemed Filed For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended, Or Subject To The Liabilities Of That Section Or Sections 11 And 12(a)(2) Of The Securities Act Of 1933, As Amended. The Information Shall Not Be Deemed Incorporated By Reference Into Any Other Filing With The Securities And Exchange Commission Made By The Company, Whether Made Before Or After Today S Date, Regardless Of Any General Incorporation Language In Such Filing, Except As Shall Be Expressly Set Forth By Specific References In Such Filing, Financial Statements And Exhibits
08/04/2024 Poseida Therapeutics: Of This Report (including Exhibit 99.1, Exhibit 99.2 And Exhibit 99.3) Is Furnished And Shall Not Be Deemed Filed For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended, Or Subject To The Liabilities Of That Section Or Sections 11 And 12(a)(2) Of The Securities Act Of 1933, As Amended. The Information Shall Not Be Deemed Incorporated By Reference Into Any Other Filing With The Securities And Exchange Commission Made By The Company, Whether Made Before Or After Today S Date, Regardless Of Any General Incorporation Language In Such Filing, Except As Shall Be Expressly Set Forth By Specific References In Such Filing, Financial Statements And Exhibits
All organization news

Documentation

IFRS/US GAAP reports

2024
I q eng
II q eng
III q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
II q eng
III q eng
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • LEI
    549300USKSDMNGMN8V04
  • SIC
    2836 BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
  • CIK
    0001661460
  • EIN
    47-2846548
Registration is required to get access.